EU invests €20m in Fabentech to enhance public health defence

The European Commission, through its Health Emergency Preparedness and Response Authority (HERA) and the European Investment Bank (EIB), has signed a €20 million agreement with French biopharmaceutical company Fabentech.

This funding will support the development and deployment of Fabentech’s broad-spectrum therapeutics designed to address biological threats to public health.

HERA’s threat analysis highlights the necessity of advancing Fabentech’s technology platform, which focusses on producing broad-spectrum polyclonal antibody fragments that identify and neutralise pathogens and toxins in the human body.

With its integrated research and development (R&D) and bioproduction capabilities, Fabentech aims to quickly develop and manufacture new immunotherapies, enhancing the response to public health emergencies.

This agreement marks the first investment under HERA Invest, with additional investments anticipated from other European companies to foster innovation in addressing priority health threats, including high pandemic potential pathogens, chemical, biological, radiological, and nuclear (CBRN) threats, and antibiotic resistance.

Attribution: The Egyptian Commission

Subediting: M. S. Salama